We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Behind Boston Scientific's Optimism for Urology Growth?
Read MoreHide Full Article
Key Takeaways
Boston Scientific's Urology sales grew 27% operationally and 5% organically in Q3 2025.
Growth was led by BSX's strong international gains and the global Stone Management franchise.
The Axonics integration and new F15 approval in Europe position Boston Scientific for a robust 2026.
Boston Scientific (BSX - Free Report) delivered solid sales in the Urology franchise in the third quarter of 2025, growing 27% operationally and 5% organically. The business specializes in devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Growth was driven by a solid international performance and the global Stone Management franchise. The Boston Scientific team had been working proactively to overcome the temporary supply-chain issues earlier in the year, aiming to steadily improve and pursue low-cost competition again.
The Axonics integration remains highly important for Boston Scientific, expanding its presence into sacral neuromodulation (SNM), a high-growth adjacency for the Urology business. The company also brings a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity. In the third quarter, performance remained below Boston Scientific’s expectations as it focuses on improving commercial execution following the unplanned commercial disruption. The company has worked through commercial model changes, some turnaround and restrengthened the team. With these developments, Boston Scientific predicts a very strong 2026 for Axonics.
Additionally, the company received approval for Axonics F15 in Europe. Boston Scientific’s strong outlook for Axonics’ business, coupled with a wide cadence of innovations across the business, supports confidence that Urology growth will improve throughout the next year.
News From BSX’s Peers
Align Technologies (ALGN - Free Report) delivered third-quarter 2025 revenues of $995.7 million, up 1.8% year over year. Clear Aligner revenues in the third quarter reached $806 million, up 2.4% year over year and also slightly up on a sequential basis. Meanwhile, Clear Aligner volume growth was mainly driven by the EMEA, APAC and Latin American regions, as well as strong sequential growth from the APAC and Latin American regions. Align Technology has also announced a series of new product innovations for iTero Digital Solutions, a comprehensive ecosystem that includes intraoral scanners and integrated software tools.
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2025 revenue totaled $2.51 billion, up 23% year over year. This was driven by growth in procedure volume, higher da Vinci system placements and an increase in the installed base of systems. In October, the FDA cleared software advancements for the Ion endoluminal system (Ion). Ion, Intuitive Surgical’s robotic-assisted bronchoscopy platform, features an ultra-thin, shape-sensing catheter designed to navigate deep into the lung.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have risen 13.1% against the industry’s 4.6% fall.
Image Source: Zacks Investment Research
Boston Scientific is trading at a forward five-year Price-to-Sales (P/S) of 6.76X compared to the industry average of 2.95X.
Image Source: Zacks Investment Research
See how analysts are projecting Boston Scientific’s 2025 earnings.
Image: Bigstock
What's Behind Boston Scientific's Optimism for Urology Growth?
Key Takeaways
Boston Scientific (BSX - Free Report) delivered solid sales in the Urology franchise in the third quarter of 2025, growing 27% operationally and 5% organically. The business specializes in devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Growth was driven by a solid international performance and the global Stone Management franchise. The Boston Scientific team had been working proactively to overcome the temporary supply-chain issues earlier in the year, aiming to steadily improve and pursue low-cost competition again.
The Axonics integration remains highly important for Boston Scientific, expanding its presence into sacral neuromodulation (SNM), a high-growth adjacency for the Urology business. The company also brings a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity. In the third quarter, performance remained below Boston Scientific’s expectations as it focuses on improving commercial execution following the unplanned commercial disruption. The company has worked through commercial model changes, some turnaround and restrengthened the team. With these developments, Boston Scientific predicts a very strong 2026 for Axonics.
Additionally, the company received approval for Axonics F15 in Europe. Boston Scientific’s strong outlook for Axonics’ business, coupled with a wide cadence of innovations across the business, supports confidence that Urology growth will improve throughout the next year.
News From BSX’s Peers
Align Technologies (ALGN - Free Report) delivered third-quarter 2025 revenues of $995.7 million, up 1.8% year over year. Clear Aligner revenues in the third quarter reached $806 million, up 2.4% year over year and also slightly up on a sequential basis. Meanwhile, Clear Aligner volume growth was mainly driven by the EMEA, APAC and Latin American regions, as well as strong sequential growth from the APAC and Latin American regions. Align Technology has also announced a series of new product innovations for iTero Digital Solutions, a comprehensive ecosystem that includes intraoral scanners and integrated software tools.
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2025 revenue totaled $2.51 billion, up 23% year over year. This was driven by growth in procedure volume, higher da Vinci system placements and an increase in the installed base of systems. In October, the FDA cleared software advancements for the Ion endoluminal system (Ion). Ion, Intuitive Surgical’s robotic-assisted bronchoscopy platform, features an ultra-thin, shape-sensing catheter designed to navigate deep into the lung.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have risen 13.1% against the industry’s 4.6% fall.
Image Source: Zacks Investment Research
Boston Scientific is trading at a forward five-year Price-to-Sales (P/S) of 6.76X compared to the industry average of 2.95X.
Image Source: Zacks Investment Research
See how analysts are projecting Boston Scientific’s 2025 earnings.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.